ADMA Biologics Inc.

ADMA | NASDAQ

Price Alert Chart Builder DCF Calculator

$9.51

+$0.40 (+4.39%)

At close: Sep 21, 2026, 4:00 PM ET

$9.54

+$0.03 (+0.32%)

After-hours: Sep 21, 2026, 7:53 PM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+4.39%

(1D)

Rating

Updated: Aug 24, 2026

77.5

Fundamentals Excellent

Market Sentiment Neutral

Moat Narrow

Full Analysis

Key Statistics

Market Data

Market Cap $2.2B

1D Range

9.19 9.53

52W Range

7.21 20.46

Valuation (TTM)

PE 13.59

PB 5.40

EV/EBITDA 9.67

Valuation (NTM)

Forward PE 9.48

Forward PEG 0.69

Price Target $18.67

Cash Flow

FCF Yield 5.3%

SBC Adj. FCF Yield 4.3%

SBC Impact -19.7%

Margins

Gross Margin 64.7%

Operating Margin 42.3%

FCF Margin 22.7%

Growth (CAGR)

Revenue 3Y | 5Y 35.0% | 54.5%

Dil EPS 3Y | 5Y 49.4% | 176.0%

FCF 3Y | 5Y 30.0% | 278.1%

Returns

ROA 24.7%

ROE 39.6%

ROIC 27.6%

Financial Health

Net Debt

$60.57M

Current Ratio 6.97

Interest Coverage 24.53

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

ADMA Biologics, Inc. functions as a biopharmaceutical company specializing in the development, manufacturing, and commercialization of advanced biologic therapies derived from blood plasma. These spec...

Sector Healthcare

Industry Biotechnology

Employees 644

IPO Date Oct 16, 2013

Website www.admabiologics.com

Fiscal Year January - December

Full Company Profile

Latest News

3 days ago · zacks.com

Adma Biologics (ADMA) Outpaces Stock Market Gains: What You Should Know

Adma Biologics (ADMA) closed the most recent trading day at $9.13, moving +2.01% from the previous trading session.

8 days ago · newsfilecorp.com

Berger Montague PC Investigates ADMA Biologics, Inc.'s Board of Directors for Breach of Fiduciary Duty (ADMA)

Philadelphia, Pennsylvania--(Newsfile Corp. - September 14, 2026) - National plaintiffs' law firm Berger Montague PC announces an investigation into potential breaches of fiduciary duty by the Board of Directors of ADMA Biologics, Inc. (NASDAQ: ADMA) ("ADMA" or the "Company"). The investigation is focused on whether the Company engaged in channel-stuffing to drive revenue growth despite declining demand for its flagship product, ASCENIV.

11 days ago · zacks.com

Adma Biologics (ADMA) Stock Falls Amid Market Uptick: What Investors Need to Know

Adma Biologics (ADMA) reached $9.23 at the closing of the latest trading day, reflecting a -1.7% change compared to its last close.

12 days ago · zacks.com

Adma Biologics (ADMA) Falls More Steeply Than Broader Market: What Investors Need to Know

Adma Biologics (ADMA) closed at $9.36 in the latest trading session, marking a -1.01% move from the prior day.

14 days ago · zacks.com

Adma Biologics (ADMA) Is Considered a Good Investment by Brokers: Is That True?

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

14 days ago · prnewswire.com

Berger Montague PC Investigates ADMA Biologics, Inc.'s Board of Directors for Breach of Fiduciary Duty (NASDAQ: ADMA)

PHILADELPHIA, Sept. 8, 2026 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces an investigation into potential breaches of fiduciary duty by the Board of Directors of ADMA Biologics, Inc. (NASDAQ: ADMA) ("ADMA" or the "Company").

18 days ago · zacks.com

Adma Biologics (ADMA) Down 4.8% Since Last Earnings Report: Can It Rebound?

Adma Biologics (ADMA) reported earnings 30 days ago. What's next for the stock?

27 days ago · newsfilecorp.com

ADMA BIOLOGICS, INC. (ADMA) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary Duty

New York, New York--(Newsfile Corp. - August 26, 2026) - Bernstein Liebhard LLP, a nationally recognized investor rights law firm, announces that it is investigating potential breaches of fiduciary duty by certain directors and officers of ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA). The investigation seeks to determine whether the Company's leadership fulfilled its obligations to shareholders and whether legal remedies may be available.